IBD in women of reproductive age: where do novel therapies fit in?

Click to increase image sizeClick to decrease image size

Declaration of interest

CP Selinger has received unrestricted research grants from Warner Chilcott, Janssen, Galapagos and AbbVie, has provided consultancy to Warner Chilcott, Dr Falk, AbbVie, Takeda, Fresenius Kabi, Eli Lilly, Galapagos, Ferring, Arena and Janssen, and had speaker arrangements with Warner Chilcott, Dr Falk, Galapagos, AbbVie, MSD, Pfizer, Eli Lilly, BMS, UCB, Fresenius Kabi, Celltrion and Takeda. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

One reviewer has received payments in the last five years for services like fees for consulting, lectures, speaker’s bureau from AbbVie, Ferring, Falk, Yansen, Takeda, Pfizer, Tillots. The remaining reviewers have no other relevant financial relationships or otherwise to disclose.

Author contributions

M Cuffe and CP Selinger developed the manuscript outline. M Cuffe wrote the draft, which was critically reviewed by CP Selinger.

Institutional review board statement

Not applicable.

Additional information

Funding

This paper was not funded.